Vanda Pharmaceuticals earns from Fanapt, Hetlioz, and Ponvory sales. It aims to diversify its portfolio with pipeline candidates like tradipitant and milsaperidone. Vanda's focus on R&D and FDA approvals is expected to drive long-term growth.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing